Cytosorbents Corporation (CTSO)

Market Cap	66.99M
Revenue (ttm)	35.33M
Net Income (ttm)	-16.11M
Shares Out	62.61M
EPS (ttm)	-0.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,276
Open	1.100
Previous Close	1.090
Day's Range	1.060 - 1.100
52-Week Range	0.700 - 1.610
Beta	1.05
Analysts	Buy
Price Target	5.50 (+414.02%)
Earnings Date	Aug 12, 2025

About CTSO

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, su...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1997
• Employees: 149
• Stock Exchange: NASDAQ
• Ticker Symbol: CTSO
• Website: https://www.cytosorbents.com

Financial Performance

In 2024, Cytosorbents's revenue was $35.59 million, an increase of 14.51% compared to the previous year's $31.08 million. Losses were -$20.72 million, -29.16% less than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CTSO stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 414.02% from the latest price.

Price Target

$5.5

(414.02% upside)

Analyst Consensus: Buy